9B90
 
 | |
9B91
 | |
9B8X
 | |
9B8Z
 | |
9B8W
 | |
9B8Y
 | |
9B92
 | |
8UN5
 | | KRAS-G13D-GDP in complex with Cpd38 ((E)-1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-2-methylenetetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)-3-(1,2,3,4-tetrahydroisoquinolin-8-yl)prop-2-en-1-one) | | Descriptor: | (2E)-1-{(3S)-4-[(7M)-7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-{[(4R,7aS)-2-methylidenetetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}quinazolin-4-yl]-3-methylpiperazin-1-yl}-3-(1,2,3,4-tetrahydroisoquinolin-8-yl)prop-2-en-1-one, GLYCEROL, GTPase KRas, ... | | Authors: | Ultsch, M.H. | | Deposit date: | 2023-10-18 | | Release date: | 2023-12-20 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (1.31 Å) | | Cite: | Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors.
Acs Med.Chem.Lett., 15, 2024
|
|
8UN3
 | | KRAS-G13D-GDP in complex with Cpd5 (1-((S)-10-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-11-chloro-7-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-3,4,13,13a-tetrahydropyrazino[2',1':3,4][1,4]oxazepino[5,6,7-de]quinazolin-2(1H)-yl)prop-2-en-1-one) | | Descriptor: | 1,2-ETHANEDIOL, 1-[(5M,8aS,13R)-5-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-2-{[(2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl]methoxy}-8a,9,11,12-tetrahydropyrazino[2',1':3,4][1,4]oxazepino[5,6,7-de]quinazolin-10(8H)-yl]prop-2-en-1-one, CHLORIDE ION, ... | | Authors: | Ultsch, M.H. | | Deposit date: | 2023-10-18 | | Release date: | 2023-12-20 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (2.07 Å) | | Cite: | Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors.
Acs Med.Chem.Lett., 15, 2024
|
|
8UN4
 | |
3L15
 | | Human Tead2 transcriptional factor | | Descriptor: | GLYCEROL, Transcriptional enhancer factor TEF-4 | | Authors: | Tomchick, D.R, Luo, X, Tian, W. | | Deposit date: | 2009-12-10 | | Release date: | 2010-04-07 | | Last modified: | 2017-11-01 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | Structural and functional analysis of the YAP-binding domain of human TEAD2.
Proc.Natl.Acad.Sci.USA, 107, 2010
|
|
5GS4
 | | Crystal structure of estrogen receptor alpha in complex with a stabilized peptide antagonist | | Descriptor: | ARG-IAS-ILE-LEU-DNP-ARG-LEU-LEU-GLN, ESTRADIOL, Estrogen receptor, ... | | Authors: | Xie, M, Wang, T, Li, Z.-G. | | Deposit date: | 2016-08-13 | | Release date: | 2017-08-30 | | Last modified: | 2018-07-18 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | Structural Basis of Inhibition of ER alpha-Coactivator Interaction by High-Affinity N-Terminus Isoaspartic Acid Tethered Helical Peptides
J. Med. Chem., 60, 2017
|
|
5GTR
 | |
6LHC
 | | The cryo-EM structure of coxsackievirus A16 empty particle | | Descriptor: | VP1, VP2, VP3 | | Authors: | He, M.Z, Xu, L.F, Zheng, Q.B, Zhu, R, Yin, Z.C, Cheng, T, Li, S.W. | | Deposit date: | 2019-12-07 | | Release date: | 2020-02-05 | | Last modified: | 2022-03-23 | | Method: | ELECTRON MICROSCOPY (3.43 Å) | | Cite: | Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
Cell Host Microbe, 27, 2020
|
|
6LHL
 | | The cryo-EM structure of coxsackievirus A16 A-particle in complex with Fab 18A7 | | Descriptor: | VP1 protein, VP2 protein, VP3 protein | | Authors: | He, M.Z, Xu, L.F, Zheng, Q.B, Zhu, R, Yin, Z.C, Cheng, T, Li, S.W. | | Deposit date: | 2019-12-09 | | Release date: | 2020-02-05 | | Last modified: | 2022-03-23 | | Method: | ELECTRON MICROSCOPY (3.07 Å) | | Cite: | Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
Cell Host Microbe, 27, 2020
|
|
6LHB
 | | The cryo-EM structure of coxsackievirus A16 A-particle | | Descriptor: | VP1, VP2, VP3 | | Authors: | He, M.Z, Xu, L.F, Zheng, Q.B, Zhu, R, Yin, Z.C, Cheng, T, Li, S.W. | | Deposit date: | 2019-12-07 | | Release date: | 2020-02-05 | | Last modified: | 2022-03-23 | | Method: | ELECTRON MICROSCOPY (3.33 Å) | | Cite: | Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
Cell Host Microbe, 27, 2020
|
|
6LHP
 | | The cryo-EM structure of coxsackievirus A16 mature virion in complex with Fab 14B10 | | Descriptor: | SPHINGOSINE, VP1 protein, VP2 protein, ... | | Authors: | He, M.Z, Xu, L.F, Zheng, Q.B, Zhu, R, Yin, Z.C, Cheng, T, Li, S.W. | | Deposit date: | 2019-12-09 | | Release date: | 2020-02-05 | | Last modified: | 2020-02-26 | | Method: | ELECTRON MICROSCOPY (3.3 Å) | | Cite: | Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
Cell Host Microbe, 27, 2020
|
|
6LHO
 | | The cryo-EM structure of coxsackievirus A16 empty particle in complex with Fab 18A7 | | Descriptor: | VP1 protein, VP2 protein, VP3 protein | | Authors: | He, M.Z, Xu, L.F, Zheng, Q.B, Zhu, R, Yin, Z.C, Cheng, T, Li, S.W. | | Deposit date: | 2019-12-09 | | Release date: | 2020-02-05 | | Last modified: | 2022-03-23 | | Method: | ELECTRON MICROSCOPY (3.13 Å) | | Cite: | Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
Cell Host Microbe, 27, 2020
|
|
6LHK
 | | The cryo-EM structure of coxsackievirus A16 mature virion in complex with Fab 18A7 | | Descriptor: | SPHINGOSINE, VP1 protein, VP2 protein, ... | | Authors: | He, M.Z, Xu, L.F, Zheng, Q.B, Zhu, R, Yin, Z.C, Cheng, T, Li, S.W. | | Deposit date: | 2019-12-09 | | Release date: | 2020-02-05 | | Last modified: | 2022-03-23 | | Method: | ELECTRON MICROSCOPY (2.65 Å) | | Cite: | Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
Cell Host Microbe, 27, 2020
|
|
6LHA
 | | The cryo-EM structure of coxsackievirus A16 mature virion | | Descriptor: | SPHINGOSINE, VP1 protein, VP2 protein, ... | | Authors: | He, M.Z, Xu, L.F, Zheng, Q.B, Zhu, R, Yin, Z.C, Cheng, T, Li, S.W. | | Deposit date: | 2019-12-07 | | Release date: | 2020-02-05 | | Last modified: | 2022-03-23 | | Method: | ELECTRON MICROSCOPY (3.56 Å) | | Cite: | Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
Cell Host Microbe, 27, 2020
|
|
6LHQ
 | | The cryo-EM structure of coxsackievirus A16 mature virion in complex with Fab NA9D7 | | Descriptor: | SPHINGOSINE, VP1 protein, VP2 protein, ... | | Authors: | He, M.Z, Xu, L.F, Zheng, Q.B, Zhu, R, Yin, Z.C, Cheng, T, Li, S.W. | | Deposit date: | 2019-12-09 | | Release date: | 2020-02-05 | | Last modified: | 2022-03-23 | | Method: | ELECTRON MICROSCOPY (3.06 Å) | | Cite: | Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
Cell Host Microbe, 27, 2020
|
|
6LHT
 | | Localized reconstruction of coxsackievirus A16 mature virion in complex with Fab 18A7 | | Descriptor: | SPHINGOSINE, VP1 protein, heavy chain variable region of Fab 18A7, ... | | Authors: | He, M.Z, Xu, L.F, Zheng, Q.B, Zhu, R, Yin, Z.C, Cheng, T, Li, S.W. | | Deposit date: | 2019-12-10 | | Release date: | 2020-02-05 | | Last modified: | 2020-02-26 | | Method: | ELECTRON MICROSCOPY (3.67 Å) | | Cite: | Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
Cell Host Microbe, 27, 2020
|
|
7WPH
 | | SARS-CoV2 RBD bound to Fab06 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, FAB06 light chain, Fab06 heavy chain, ... | | Authors: | Lin, J.Q, El Sahili, A, Lescar, J. | | Deposit date: | 2022-01-23 | | Release date: | 2022-03-30 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.89 Å) | | Cite: | Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth.
Nat Commun, 13, 2022
|
|
7WPV
 | | Fab14 - a SARS-CoV2 RBD neutralising antibody | | Descriptor: | Fab14 heavy chain, Fab14 light chain | | Authors: | Lin, J.Q, El Sahili, A, Lescar, J. | | Deposit date: | 2022-01-24 | | Release date: | 2022-03-30 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.46 Å) | | Cite: | Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth.
Nat Commun, 13, 2022
|
|
9B94
 | |
